Myeloma News

In this video, Nisha Joseph, MD, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses how multiple myeloma awareness can be increased among the general public.

In this video, Nisha Joseph, MD, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses the major areas of unmet need in multiple myeloma treatment.

In this video, Nisha Joseph, MD, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses some of the new treatments in the pipeline for multiple myeloma.

In this video, Nisha Joseph, MD, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses the mysteries still surrounding who is most likely to develop multiple myeloma.

In this video, Nisha Joseph, MD, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses the new wave of novel therapeutics on the market to treat multiple myeloma.

A meta-analysis of patients who underwent chimeric antigen receptor T-cell therapy for advanced blood cancers showed low prevalence of cardiovascular adverse events.

Older adults diagnosed with a blood cancer exhibited similar rates of cognitive decline as cancer-free controls, according to study results.

The timing with which patients with newly diagnosed multiple myeloma began treatment with oral antimyeloma medications varied greatly by age and race, according to retrospective study results.

A novel therapeutic approach may improve the persistence and functionality of chimeric antigen receptor T cells, helping to prevent relapse.

SGLT2 inhibition may prevent cancer therapy-related cardiac dysfunction and improve other outcomes in patients with diabetes undergoing cancer therapy, researchers reported.